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Abstract
Background: Cancer cells have increased levels of transferrin receptor and lower levels of ferritin, an iron deficient
phenotype that has led to the use of iron chelators to further deplete cells of iron and limit cancer cell growth. As
cancer cells also have increased reactive oxygen species (ROS) we hypothesized that a contrarian approach of
enhancing iron entry would allow for further increased generation of ROS causing oxidative damage and cell
death.
Methods: A small molecule library consisting of ~11,000 compounds was screened to identify compounds that
stimulated iron-induced quenching of intracellular calcein fluorescence. We verified the iron facilitating properties
of the lead compound, LS081, through 55Fe uptake and the expression of the iron storage protein, ferritin. LS081-
induced iron facilitation was correlated with rates of cancer cell growth inhibition, ROS production, clonogenicity,
and hypoxia induced factor (HIF) levels.
Results: Compound LS081 increased 55Fe uptake in various cancer cell lines and Caco2 cells, a model system for
studying intestinal iron uptake. LS081 also increased the uptake of Fe from transferrin (Tf). LS081 decreased
proliferation of the PC-3 prostate cancer cell line in the presence of iron with a lesser effect on normal prostate
267B1 cells. In addition, LS081 markedly decreased HIF-1a and -2a levels in DU-145 prostate cancer cell line and
the MDA-MB-231 breast cancer cell lines, stimulated ROS production, and decreased clonogenicity.
Conclusions: We have developed a high through-put screening technique and identified small molecules that
stimulate iron uptake both from ferriTf and non-Tf bound iron. These iron facilitator compounds displayed
properties suggesting that they may serve as anti-cancer agents.
Background
Iron is an essential element required for many biological
processes from electron transport to ATP production to
heme and DNA synthesis with the bulk of the iron
being in the hemoglobin of circulating red blood cells
[1,2]. Too little iron leads to a variety of pleiotropic
effects from iron deficiency anemia to abnormal neuro-
logic development, while too much iron may result in
organ damage including hepatic cirrhosis and myocar-
diopathies. The system for the maintenance of iron
homeostasis is complex. Approximately 1 mg of the iron
utilized daily for the synthesis of nascent red blood cells
is newly absorbed in the intestine to replace the amount
lost by shed epithelial cells and normal blood loss. The
remainder of the iron incorporated into newly synthe-
sized hemoglobin is derived from macrophages from
catabolized senescent red blood cells. Hence, the uptake
of iron for its final incorporation into hemoglobin or
other ferriproteins requires 3 different transport path-
ways: intestinal iron absorption, iron release from
macrophages, and iron uptake into erythroid precursors
and other iron-requiring cells.
In vertebrates, iron entry into the body occurs primar-
ily in the duodenum, where Fe3+ is reduced to the more
soluble Fe2+ by a ferrireductase (DcytB), which trans-
ports electrons from cytosolic NADPH to extracellular
acceptors such as Fe3+ [3]. The Fe2+ is transported
across the brush border membrane (BBM) of duodenal
enterocytes via the transmembrane protein, DMT1
(divalent metal transporter, also known as SLC11a2,
DCT1, or Nramp2) [4,5]. Subsequently, the internalized
Fe2+ is transported across the basolateral membrane
(BLM) by the transmembrane permease ferroportin
(FPN1, also known as SLC40a1) [3,6] in cooperation
with the multicopper oxidase Hephaestin (Heph) [7,8].
The exit of iron from macrophages onto plasma
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transferrin (Tf) is also mediated by the interaction of
FPN1 and Heph [9]. The efflux of iron into the systemic
circulation from the enterocyte and the macrophage is
negatively regulated by hepcidin, the iron-stores regula-
tor. Hepcidin binds to FPN1 promoting phosphoryla-
tion, internalization, and subsequent catabolism of FPN1
via proteasomes [10].
In erythroid precursor cells, and indeed in all non-
intestinal cells, iron uptake is mediated by receptor
mediated endocytosis of ferri-transferrin (Fe-Tf)
although routes for non-transferrin bound Fe (NTBI)
also exist. Fe-Tf binds to the transferrin receptor (TfR)
on the cell surface [11] and the Fe-Tf complex is inter-
nalized into endosomes with subsequent acidification of
the endosome which releases Fe3+ from Tf. The Fe3+ is
then reduced to Fe2+ by the ferrireductase STEAP 3 [12]
and the Fe2+ transported by DMT1 into the cytosol.
There are two situations in which one could envision
a benefit from being able to accelerate or otherwise
increase cellular uptake of iron. First, iron deficiency is
endemic in much of the world resulting in decreased
ability to work especially in women of child bearing age
and in impaired neurologic development in children
[13,14]. Common factors leading to an imbalance in
iron metabolism include insufficient iron intake and
decreased absorption due to poor dietary sources of iron
[15]. In fact, Fe deficiency is the most common nutri-
tional deficiency in children and the incidence of iron
deficiency among adolescents is also rising [16]. Iron
deficiency ultimately leads to anemia, a major public
health concern affecting up to a billion people world-
wide, with iron deficiency anemia being associated with
poorer survival in older adults [17]. As much of iron
deficiency is nutritional, drugs that promote iron uptake
could be beneficial without the necessity of changing
economic and cultural habits that dictate the use of iron
poor diets.
A second, and separate, situation exists in malignan-
cies. Cancer cells often have an iron deficient phenotype
with increased expression of TfR, DMT1, and/or Dcytb
and decreased expression of the iron export proteins
FPN1 and Heph [18-20]. Since higher levels of ROS are
observed in cancer cells compared to non-cancer cells
drugs that stimulate iron uptake into cancer cells might
further increase ROS levels via the Fenton reaction. The
increased ROS might lead to oxidative damage of DNA,
proteins, and lipids [21,22] and cell death or potentiate
cell killing by radiation or radiomimetic chemotherapeu-
tic agents. Further, increased intracellular levels of Fe
would increase the activity of prolyl hydroxylases poten-
tiating hydroxylation of HIF-1a and HIF-2a, transcrip-
tion factors that drive cancer growth, resulting in
decreased HIF expression via ubiquination and protea-
some digestion.
Wessling-Resnick and colleagues have used a cell-
based fluorescence assay to identify chemicals in a small
molecule chemical library that block iron uptake
[23-25]. While some of the chemicals identified inhib-
ited Tf-mediated iron uptake [23] more recent studies
utilizing a HEK293T cell line that stably expresses
DMT1 have identified chemicals that act specifically on
the iron transporter [24,25]. In the current study, we
have used a similar assay to identify chemicals that
increase iron uptake into cells and demonstrate that
these chemicals are effective in increasing iron transport
across Caco2 cells, a model system for studying intest-
inal iron absorption, and increasing iron uptake into
various cancer cell lines, favourably altering several
aspects of the malignant phenotype.
Methods
Cell lines and Chemicals
All antibodies were purchased from Santa Cruz Biotech-
nology, Inc. (Santa Cruz, CA) except for rabbit anti-
HIF-1a and -2a which were purchased from Novos
Biologicals (Littleton, CO). All analytical chemicals were
from Sigma-Aldrich (St. Louis, MO). The chemical
libraries were obtained from ChemDiv (San Diego, CA)
and TimTec (Newark, DE). CM-H2DCFDA (5-(and-6)-
chloromethyl-2’,7’-dichlorodihydrofluorescein diacetate,
acetyl ester) or DCFDA and calcein-AM were from
Invitrogen (Carlsbad, CA). The cell lines K562, PC-3,
Caco2, MDA-MB231, and 267B1 were obtained from
ATCC (Bethesda, MD). RPMI1640 and DMEM culture
media and fetal calf serum (FCS) were obtained from
Atlanta Biologicals (Lawrenceville, GA).
Screening for chemicals that increase iron uptake
K562 cells were loaded with calcein by incubating cells
with 0.1 μM of Calcein-AM for 10 min in 0.15 M NaCl-20
mM Hepes buffer, pH 7.4, with 0.1% BSA at 37°C followed
by extensive washing with NaCl-Hepes buffer to remove
extracellular bound calcein, and aliquoted at 5 × 104 - 1 ×
105 cells/well in 96-well plates containing test compounds
at 10 μM and incubated for 30 min in a humidified 37°C
incubator with 5% CO2 before baseline fluorescence was
obtained at 485/520 nm (excitation/emission) with 0.1%
DMSO as the vehicle control and DTPA as a strong iron
chelator control to block all iron uptake. The fluorescence
was then obtained 30 min after addition of 10 μM ferrous
ammonium sulfate in 500 μM ascorbic acid (AA). The
percentage of fluorescence quench was calculated relative
to 200 μM DTPA added as a blocking control and DMSO
as a vehicle control as follows:
F = (F0 - Ff)/F0 (1)
where Δ F is the change in fluorescence, or fluores-
cence quench, observed in any well, F0 represents the
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fluorescence after 30 min of compound, and Ff repre-
sents the fluorescence 30 min after addition of Fe.
These results were normalized to the blocking and vehi-
cle controls as follows:
Fn = (Fcompound - Fmin)/(Fmax - Fmin) (2)
where Δ Fn is the normalized quench observed after
addition of iron, Fcompound is the Δ F observed with com-
pound, Fmin is the average Δ F of the DMSO control; and
Fmax is the average Δ F of the DTPA control. With this
normalization 100% indicates that a test compound is as
potent as DTPA in blocking iron-induced quenching and
0% indicates no inhibition of iron quenching by a test
compound or the same quench as observed with the
DMSO vehicle control. Compounds with Δ Fn between
0% and 100% are defined as inhibitors of iron uptake.
Negative values for Δ Fn represent compounds that facili-
tate iron uptake into cells. Our criteria for active com-
pounds to be further investigated was arbitrarily set as Δ
Fn = 50-100% quenching for iron uptake inhibitors and <
-50% quenching for iron uptake facilitators.
55Fe uptake into K562 cells
3 × 105 K562 cells in 300 μl NaCl-Hepes-0.1% BSA were
incubated for 30 min with test compound at various
concentrations as indicated in a humidified 37°C incuba-
tor with 5% CO2. A mixture of
55Fe- and AA was then
added for a final concentration of 1 μM 55Fe -1 mM AA
and the cells incubated for an additional 60 min. The
reaction was stopped by the addition of ice-cold quench
buffer (NaCl-Hepes with 2 mM EDTA) followed by
extensive washing of the cells which were then dispersed
in scintillation fluid and 55Fe radioactivity determined in
a Tri-carb 2900 TR liquid scintillation analyzer (Packard
BioScience Company, Meriden, CT).
Preparation of medium containing 10% FCS with iron-
saturated Tf
Iron on the Tf in FCS was removed from the Tf by low-
ering the pH to 4.5 followed by dialysis against 0.1 M
citrate buffer, pH 4.5, in the presence of Chelex for 16
hours, and dialyzed again against HEPES buffered saline,
pH 7.4, in the presence of Chelex. FeNTA (1:2 molar
ratio for Fe: NTA) was then added to the now iron-free
FCS at 1 mM final concentration followed by extensive
dialysis against HEPES buffered saline, pH 7.4. The
resulted FCS containing iron-saturated Tf was added
into RPMI1640 to make the medium containing 10%
iron-saturated FCS.
Western blot analysis of ferritin, TfR, and HIF-1a and -2a
PC-3 cells were plated into 6-well plates at cell density
of 5 × 105 cells/well for overnight attachment before
addition of test compound or vehicle control for
16 hours. The cells were then lysed with RIPA buffer
(50 mM Tris-HCl, 1% NP-40, 0.25% Na-deoxycholate,
150 mM NaCl, 1 mM EDTA, pH 7.4) and the lysates
separated on SDS-PAGE with subsequent transfer to
nitrocellulose for western blot analysis using the follow-
ing antibodies: mouse anti-human ferritin-heavy chain,
mouse anti-human TfR, anti-HIF-1a or -2a, and rabbit
anti-human b-actin. Results were quantitated by densi-
tometry and relative densitometric units expressed as
the ratio of protein of interest to actin.
55Fe uptake and transport in Caco2 cells
Caco2 cells were seeded in 6.5 mm bicameral chambers
in 24-well plates, grown in 10% FCS-minimum essential
medium for ~2 week to reach a transepithelial electrical
resistance (TEER) of 250 .cm2. The cells were incubated
in serum-free DMEM with 0.1% BSA overnight and the
inserts then transferred to fresh 24-well plates with the
basal chambers containing 700 μL of 20 μM Apo-Tf in
DMEM. Test compound at concentrations of 0-100 μM
in a total volume of 150 μl were added to the top cham-
ber, incubated for 60 min at 37°C, 5% CO2 incubator,
followed by the addition of 55Fe to the top chamber at a
final concentration of 0.125 μM 55Fe in 1 mM AA. At
various times up to 2 hours, the top and bottom cham-
ber buffer were removed, the cell layer washed exten-
sively with Hepes-NaCl containing 0.1 mM EDTA, and
55Fe radioactivity determined in the upper and lower
chamber buffers and the cell layer.
ROS measurement
To determine if compound affected cellular production
of ROS, 5 × 105 K562 cells were washed, treated for
30 min with compound in Hepes-NaCl buffer, and
intracellular levels of ROS detected with CM-H2DCFDA
by flow cytometry as described [26]. ROS levels are pre-
sented as mean fluorescence intensity in the appropriate
gated areas. K562 cells exposed to 10 μM H2O2 were
used as positive control for ROS generation.
Cell proliferation and colony formation assays
To assess cell proliferation PC-3 cells were seeded into
96-well plates at 1 × 104/well for 24 hr to allow for cell
attachment. Cells were treated with 0.1% DMSO, 10 μM
ferric ammonium citrate, 10 μM LS081, or the combina-
tion of 10 μM Fe + 10 μM LS081 in RPMI1640-10%
FCS for 24-72 hr with the treatment media being
replenished every 24 hr. Cell proliferation was accessed
24, 48, or 72 hr after treatment. In separate experiments,
PC-3 or 267B1 cells were plated in 96-well plates at 1 ×
104/well in RPMI1640 containing 10% FCS overnight
before 24 hr treatment with 0.1% DMSO, 2 μM ferric
ammonium citrate, 3 or 10 μM LS081 ± Fe in serum-
free-RPMI1640, with an additional 24 hr incubation in
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RPMI-1640-10% FCS without LS081. Cell proliferation
was assayed with CellTiter 96 AQueous Non-Radioactive
Cell Proliferation Assay (Promega) kit on a Synergy 2
Spectrophotometric Analyzer (BioTek Inc., Winooski,
Vermont) with wavelength of 490 nM and the results
standardized to the percentage of inhibition induced by
DMSO alone. Cell viability was assessed by Trypan blue
exclusion.
Colony formation was assayed in PC-3 cells by plating
500 cells/well in 6-well plates in 10% FCS-RPMI1640 for
48 hr, followed by incubation with 0.1% DMSO, 10 μM
ferric ammonium citrate, 3 or 10 μM LS081 ± ferric
ammonium citrate for an additional 48 hours, after
which the media was replaced with 10% FCS-RPMI1640.
The cells were cultured for an additional 10-14 days and
then stained with Crystal violet before colonies consist-
ing of more than 50 cells were enumerated.
Results
A cell based fluorescence assay to screen small molecules
that increase iron transport into cells
We utilized an intracellular calcein fluorescence screen-
ing method modified from Brown et al. [23] to screen a
library consisting of ~11000 small molecules for their
ability to increase or decrease iron uptake into cells. As
noted in the Method, compounds which enhanced the
calcein fluorescence quenching induced by iron were
considered to be iron facilitators while those that
decreased fluorescence quenching were considered inhi-
bitors of iron uptake. In the initial screening of the com-
pounds obtained from ChemDiv thirty compounds
exhibited negative values for Δ Fn, i.e. Δ Fn < -50% and
were therefore defined as iron facilitators including a
number of hydrazone compounds. A similar number of
compounds had Δ Fn = 50-100% and were defined as
iron uptake inhibitors. About 10 of these inhibitors
blocked the in vitro quenching of calcein by iron and
were therefore presumably iron chelators. An additional
80 structural analogs of the hydrazone class of facilitators
obtained from TimTec were subsequently assessed with
16 more facilitators identified. The ability to facilitate
iron uptake was verified using a dose response curve
from 0.1 - 100 μM of a putative facilitator with the same
calcein quenching assay as well as by measuring the effect
of the presumed facilitators on 55Fe uptake into K562
cells. Additionally, we arbitrarily chose as the lead com-
pound LS081, the first compound to be verified by a
dose-response curve (Figure 1). The ability to facilitate
iron uptake was confirmed by dose response curves in 14
of the 16 facilitators identified on the initial screen. The
EC50 for LS081 was 1.22 ± 0.48 μM with a range of EC50
of 0.5-2 μM for the remainder of the iron facilitators.
Within the range of concentrations used over the length
of the screening neither cell number nor cell viability was
affected; in addition, the chemicals did not affect the
in vitro quenching of calcein by iron (data not shown).
Caco2 cells grown in bicameral chambers for 2-3
weeks to reach the desired trans-epithelial electrical
resistance were used as a model for intestinal iron
absorption. Under these conditions the Caco2 cells dif-
ferentiate to form a confluent, polarized monolayer with
the brush border membrane of the apical surface in
contact with the buffer of the top chamber which then
mimics the intestinal lumen and the basal layer in con-
tact with the bottom chamber which represents the sys-
temic circulation. This model allows assaying in the
presence of LS081 the transport of 55Fe from the apical
chamber into the cells and then into the bottom cham-
ber. In this model over 2 hours, LS081 increased 55Fe
uptake into the Caco2 cells and into the basal chamber
by 4.0 ± 0.66 and 3.71 ± 0.29 fold, respectively, com-
pared to the DMSO-treated control (mean fold change
± SEM of 3 experiments) with P < 0.001 for both uptake
and transport into the basal chamber.
Effect of the iron facilitator LS081 on intracellular levels
of ferritin
To determine if the increased intracellular iron entered
into a metabolically active pool of iron, cellular ferritin
levels were measured in PC-3 cells at various times after
the addition of LS081. The effects of LS081 on ferritin
expression were determined under two conditions:
RPMI1640-10% FCS to which 2 μM ferric ammonium
citrate was added or RPMI with 10% iron saturated
FCS. As shown in Figure 2, LS081 at 3 and 10 μM
Figure 1 Dose response curve of LS081 on 55Fe uptake in K562
cells. 55Fe uptake was measured as described in the Methods.
Briefly, 3 × 105 K562 cells were incubated with LS081 for 30 min at
concentrations of 0.1-100 μM prior to the addition of 1 μM 55Fe-1
mM AA with subsequent determination of intracellular 55Fe
radioactivity. Results were expressed as fold increase in 55Fe
radioactivity relative to cells treated with 0.1% DMSO alone. Shown
are the means ± SEM of 3 separate experiments with triplicates for
each experiment. The insert shows the chemical structure of LS081.
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stimulated ferritin synthesis from both ferric ammonium
citrate and iron saturated Tf. In preliminary experiments
the level of ferritin protein was not significantly
increased by compound alone (data not shown).
Iron facilitation is cytotoxic to cancer cells
We examined the effect of the iron facilitator LS081 on
ROS generation using DCFDA whose fluorescence
intensity is increased in response to elevated intracellu-
lar ROS. As shown in Figure 3, K562 cells had signifi-
cantly increased levels of ROS production when exposed
to LS081 in the presence of ferric ammonium citrate
but not with iron or LS081 alone.
The proliferation of PC-3 cells, a prostate cancer cell
line, was not inhibited by 10 μM ferric ammonium
citrate or 10 μM LS081 when cultured in 10% FCS-
RPMI1640 for 24 or 48 hrs (Table 1) or 72 hr (data not
shown). However, as also shown in Table 1, treatment
with 10 μM LS081 plus 10 μM ferric ammonium citrate
for 24 hr or 48 hr significantly reduced the number of
cells relative to controls. When grown in serum-free
medium (Figure 4), 267B1 cells, an immortalized,
non-malignant prostate cell line, showed slight growth
inhibition with 3 or 10 μM LS081 alone with no poten-
tiation of growth inhibition by the addition of 2 μM fer-
ric ammonium citrate. In contrast, when PC-3 cells were
grown in serum-free medium, growth inhibition was far
greater for the combination of 2 μM ferric ammonium
citrate with either 3 μM LS081 (36 ± 6% inhibition) or
10 μM LS081 (64 ± 8% inhibition) compared to LS081
alone (14 ± 1% or 37 ± 8% inhibition for 3 or 10 μM,
respectively) (Figure 4, n = 3 experiments). 2 μM ferric
ammonium citrate alone did not affect cell proliferation
compared to vehicle control (data not shown).
Effect of the iron facilitator LS081 on clonogenic potential
on prostate cancer cells
To determine the effect of LS081 on the clonogenic
potential of prostate cancer cells colony formation
assays were performed on PC-3 cells in the presence of
ferric ammonium citrate in RPMI1640 supplemented
with 10% FCS (Figure 5). In combination with iron,
Figure 2 The effect of LS081 on ferritin expression. PC-3 cells were treated for 16 hr with DMSO alone, or 3 or 10 μM LS081 in the presence
of non-transferrin-bound-iron (ferric ammonium citrate, left panel) or transferrin-bound-iron (Fe-saturated-Tf, right panel). The cellular proteins
were separated by SDS-PAGE, and ferritin heavy chain, and b-actin detected by Western blotting as described in the Methods. The top panel
shows a representative autoradiography. The bottom panel shows the ratio of ferritin to the actin loading control by densitometric analysis
(mean values ± SEM of 3-4 separate experiments). *: p < 0.05, **: p < 0.01 compared to DMSO alone by 1-way ANOVA with Tukey’s posttests.
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LS081 at concentrations of 3 or 10 μM significantly
reduced the number of colonies compared to that trea-
ted with iron alone or LS081 alone. Reduced colony for-
mation by the combination of Fe and LS081 were also
seen in another prostate cancer cell line, DU145, com-
pared to Fe alone (data not shown).
Effect of the iron facilitator LS081 on the level of HIF-1a
and -2a protein
We investigated if the iron facilitating compound LS081
would affect the level of the transcription factors HIF-
1a and -2a. Because the level of HIF-1a in PC-3 cells
was too low to be detected by Western blot analysis,
especially when cultured at normal oxygen concentra-
tions, we used the prostate cancer cell line DU145 cul-
tured in 1% oxygen as this cell line expressed levels of
HIF-1a that could be detected by Western blot analysis.
LS081 plus Fe significantly reduced the level of HIF-1a
in DU 145 cells (Figure 6A). The effect of LS081 on the
level of HIF-2a was also examined using breast cancer
cell line MDA-MB-231, because the levels of HIF-2a
were too low in prostate cancer cell lines to be detected
by Western blot analysis. LS081 significantly reduced
HIF-2a expression in MDA-MB-231 cells cultured
under normoxic conditions in medium containing 10%
FCS (Figure 6B).
Discussion
As noted by Wessling-Resnik and colleagues in their
search for iron uptake inhibitors chemical genetics, i.e. the
use of small molecules to perturb a physiologic system,
has the ability to shed light on mechanisms of the pathway
that is being disturbed [25]. Additionally, compounds that
perturb iron uptake could have beneficial, medicinal
effects. For example, small molecules which stimulate iron
absorption might be used as adjuncts to diets that are
iron-deficient. Conversely, molecules that blocked iron
uptake might counter the increased iron absorption and
resultant iron toxicity often seen in widely prevalent dis-
eases such as sickle cell disease and the thalassemias. Wes-
sling-Resnik has screened chemical libraries to identify
chemicals that block iron uptake [23] but also found “acti-
vators” of iron uptake which were postulated to have
potential as agents to relieve iron deficiency. In the current
study we have adapted their calcein-based cell assay and
identified compounds that increase iron uptake into
Caco2 cells, as a model system for intestinal transport, and
into various cancer cell lines, thereby altering several
aspects of the malignant phenotype.
In our assay, intracellular calcein fluorescence in K562
cells was quenched upon extracellular iron being trans-
ported into the cells. Iron facilitation was defined as
fluorescence quenching greater in the presence of a test
compound compared to vehicle control. In addition,
none of the facilitators appeared to be iron chelators as
the chemicals did not compete with iron for calcein
quenching in an in vitro assay and the iron facilitators
affected the cell cycle differently from the iron chelator
deferoxamine (data not shown). We did, however, find a
number of chemicals that inhibited iron uptake and sev-
eral of these chemicals appeared to be iron chelators by
an in vitro assay. Notwithstanding that the faciltators
inhibited cell proliferation there was no evidence that
the chemicals caused cell lysis as cell number was not
diminished during the screening assays or during subse-
quent measurements of 55Fe uptake.
Table 1 The effect of LS081 and iron on the proliferation
of PC-3 cells
Treatment 24 hours 48 hours
DMSO 1.00 ± 0.00* 1.00 ± 0.00*
10 μM Fe 1.13 ± 0.04*** 1.02 ± 0.06*
10 μM LS081 1.05 ± 0.05** 1.01 ± 0.03*
10 μM Fe and LS081 0.81 ± 0.01 0.80 ± 0.09
PC-3 cells at a density of 1 × 104 in RPMI1640-10% FCS were seeded into 96-
well plates for 24 hrs prior to the addition of 0.1% DMSO ± 10 μM ferric
ammonium citrate or 10 μM LS081 ± 10 μM ferric ammonium citrate. Cell
proliferation was assayed at 24 or 48 hrs after treatments as described in the
Methods and the fold-change calculated compared to DMSO alone. Presented
are the means of the fold change ± SEM of 3 independent experiments with
each experiment performed in 3-4 replicates. * indicates P < 0.05, ** P < 0.01,
*** P < 0.001 compared to Fe plus LS081 by 2-way ANOVA with Bonferroni’s
posttests.
Figure 3 The effect of LS081 on ROS generation. Approximately
5 × 105 K562 cells were treated for 30 min with 0.1% DMSO alone,
10 μM ferric ammonium citrate alone, 3 or 10 μM LS081 alone, or
the combination of Fe and LS081 at the indicated concentrations.
The cells were then incubated with DCFDA and fluorescence
measured by a BD Calibur Flow cytometer expressing the
fluorescence as the mean total fluorescence intensity in the gated
area. Shown are the means ± SEM of 3 separate experiments with
2-3 replicates for each experiment. *** denotes P < 0.001 compared
to the DMSO, Fe, or LS081 alone by 1-way ANOVA with Tukey’s
posttests.
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In iron uptake whether from NTBI, in the case of
enterocytes, or from ferri-Tf, in the case of all other cell
types, the uptake occurs by iron being transported
through DMT1. The facilitators could act by activating
DMT1, repositioning DMT1 within the cell to more effi-
ciently transport iron, or activating another transporter.
DMT1 is a highly insoluble membrane protein making it
difficult to determine the effect of the facilitators on
DMT1 transport activity in an in vitro system; however, a
clue to the mode of action of the facilitators comes from
our observation that LS081 increased iron uptake when
the sole source of iron was ferri-Tf. Iron uptake from Tf
requires that the Tf undergo receptor mediated endocy-
tosis and DMT1 is part of the internalized endosome.
Hence, for more iron to be delivered to a cell by ferri-Tf
the endosomes containing DMT1 must cycle into and
out of the cell more rapidly. When iron is delivered by
ferri-Tf the rate limiting step in iron uptake is the length
of the transferrin cycle, that is the time for ferri-Tf to
undergo endocytosis, release iron from Tf into the endo-
some, and for the now apo-Tf still bound to the TfR to
undergo exocytosis and be released from the TfR at the
cell surface. If the facilitator shortened the length of the
Tf cycle then DMT1 would be internalized more rapidly
and the iron from Tf could be delivered faster. Inhibitors
of iron uptake from ferri-Tf have been shown to
adversely affect the Tf cycle [27]. In enterocytes we and
others have shown that DMT1 is internalized upon expo-
sure of the duodenum and Caco2 cells to Fe. Hence,
increasing the rate of DMT1 internalization would also
increase iron uptake in the enterocytes.
While we presume that LS081 acts via DMT1 by alter-
ing the kinetics of DMT1 internalization there are other
routes for iron uptake that could be affected. For exam-
ple, lipocalin (also known as NGAL or 24p3), the L-type
Ca2+ channel, and Zip14, a member of zinc transporter
family, all have been demonstrated to be iron transpor-
ters or channels [28-30]. Whether these potential routes
of iron entry are affected by the iron facilitators is not
known but these alternative minor routes for iron trans-
port function with NTBI and not with ferri-Tf and
could not explain, therefore, how the facilitators affect
uptake from ferri-Tf.
Whatever the mechanism(s) by which iron uptake
facilitation occurs the Fe that gains entry to the cell
Figure 4 Effect of LS081 on the proliferation of the prostate cancer cells and non-malignant prostate cells. Both prostate cancer cell line
PC-3 and the immortalized, non-malignant prostate cell line 267B1 cells grown in serum-free RPMI1640 with 0.1% bovine serum albumin were
treated with 0.1% DMSO or with 3 or 10 μM LS081 ± 2 μM ferric ammonium citrate for 24 hr followed by an additional 24 hr in RPMI1640-10%
FCS before cell proliferation was assayed by MTS. The results are expressed as growth inhibition relative to the DMSO controls (means ± SEM of
3-4 independent observations with four replicates in each observation). *: P < 0.05, **: P < 0.01 comparing with or without Fe conditions by 2-
way ANOVA with Bonferroni’s posttests.
Figure 5 The effect of LS081 on colony formation of PC3 Cells.
PC-3 cells in 10% FCS-RPMI1640 were seeded at a density of 500
cells/well into 6-well plates. After 24 hrs, cells were treated with
0.1% DMSO, 3 or 10 μM LS081 ± 10 μM ferric ammonium citrate for
48 hrs. The medium was replaced with 10% FCS-RPMI1640 and the
cells were allowed to grow for ~ 10-14 days before Crystal violet
staining and counting of colonies. Shown are the mean numbers of
colonies ± SEM of 3-4 of independent observations with duplicates
or triplicates for each observation. **: P < 0.01 compared to either
Fe alone or 3 μM LS081 alone; ***: p < 0.001 compared to Fe alone
or 10 μM LS081 alone by 1-way ANOVA with Newman-Keuls’s
posttests.
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enters a pool of metabolically active iron as evidenced
by several observations. First, cellular ferritin levels
increased in the presence of LS081 whether iron was
offered as non-Tf or Tf-bound iron. Second, HIF1a and
2a protein expression was decreased. Third, the colony
forming ability of prostate cancer cell lines was
decreased. Fourth, LS081 increased the level of ROS.
It is interesting to consider the effects of iron facilita-
tion on the levels of ROS as a possible explanation for
the decreased cell proliferation and clonogenicity we
observed in cancer cells. ROS levels are increased in
cancer cells and it is possible that the additional ROS
generation by LS081 exceeds cellular defences. Elevated
ROS might then make LS081 treated cells more sensi-
tive to radiation therapy and radiomimetic drugs, a
hypothesis that is being actively pursued. The idea of
disturbing the redox balance in cancer cells as a
therapeutic approach for cancer has been postulated by
other investigators [31-33]. Some conventional che-
motherapy agents such as melphalan, cisplatin, anthra-
cyclines, or bleomycin, are known to increase ROS by
compromising the ROS scavenging capability of cancer
cells [34-36]. Dicholoracetate, an inhibitor of pyruvate
dehydrogenase kinase, stimulates ROS production and
elicits apoptosis in cancer but not in normal cells [37].
Moreover, reducing ROS scavengers by inhibition of
glutamate-cysteine ligase, the rate limiting enzyme in
glutathione synthesis, increases radiosensitivity of cancer
cells [38]. In addition, metal-binding compounds have
been considered to be potential anti-cancer agents and
have demonstrated anticancer activity [39]. Although
some compounds appear to act via metal chelation,
others appear to increase intracellular metal concentra-
tions, suggesting different mechanisms of action. For
Figure 6 The effect of LS081 on the expression of HIF1a and HIF2a. MDA-MB231 and DU145 cells were treated with 10 μM LS081 in 10%
FCS-RPMI1640 ± 2 μM ferric ammonium citrate for 16 hr before harvesting for Western blot detection of HIF-1a and 2a as described in the
Methods. The Western blots were quantitated by densitometry and the amounts of HIF as the ratio of HIF-1a or HIF-2a to the actin loading
control were expressed relative to the DMSO control. The left panels are representative Western blots. A, HIF-1a was detected in DU145 cells
cultured at 1% oxygen concentration (hypoxic). In B, HIF-2a was detected in MDA-MB231 cells grown in normal oxygen tension (21%). The right
panels show the reduction of HIF-1a or -2a in the treated cells compared to control (means ± SEM of 3-4 experiments). *: p < 0.05; **: P < 0.01
compared to DMSO by 1-way ANOVA with Tukey’s posttests.
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example, clioquinol induces apoptosis of prostate cancer
cells by increasing intracellular zinc levels [40], and the
anti-malarial drug artemisinin has anti-cancer activity
that may be mediated by Fe2+ and/or heme [41,42]. The
potential toxicity of excess of iron in cancer cells sug-
gests the benefit of identifying molecules that promote
iron uptake into cancer cells triggering more efficient
cell death.
Hypoxia is a common feature of most solid tumors
with concomitant increased expression of the HIF-1a or
HIF-2a components of the HIF transcription factor
[43,44]. Elevated levels of HIF-1a or HIF-2a are poor
prognostic indicators in a variety of tumors [45]. Under
normoxic conditions, both HIF-1a and -2a are hydroxy-
lated by an iron-dependent prolyl hydroxylase (PHD),
which requires a ferrous ion at the active site, with sub-
sequent hydroxylation ubiquitination by the von Hipple-
Lindau tumor suppressor (VHL) and then proteasome
degradation. Higher levels of intracellular iron could
facilitate hydroxylation leading to increased ubiquitiza-
tion and subsequent proteosome degradation of HIF-1a
and -2a. HIF expression is important in cancer growth
via several mechanisms including neo-vascularization.
While HIF-1a and -2a have been targets for drug devel-
opment [46,47] there is as yet no clinically active drug
that specifically targets HIF expression. Presumably
LS081 induced reduction in HIF-1a and -2a is directly
related to iron facilitation with increased activity of
PHD from increased cellular iron, an hypothesis sup-
ported by loss of PHD activity and HIF1a stabilization
when cellular Fe uptake is limited by TfR knockdown
[48].
Conclusions
In summary, we identified a series of compounds cap-
able of increasing iron uptake into cells. The lead com-
pound, LS081, facilitated iron uptake which resulted in
reduced cancer cell growth, colony formation, and
decreased HIF-1a and -2a protein levels, suggests that
this class of compounds could be a useful anti-cancer
agent. In addition, the ability of these compounds to
affect iron uptake in a model system of intestinal iron
absorption suggests, also, that these compounds have a
more general clinical utility for the management of iron
deficiency.
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